Showing 1 - 10 of 15 Respiratory Tract (Lung and Bronchial) Diseases
A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3)

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary e ... Read more >

A151216 - Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery ALCHEMIST

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >

EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker

Status: Open Not Enrolling

Investigator: Sindhu Nair

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carbop ... Read more >

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such ... Read more >

NRG-LU005

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene ... Read more >

Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

The goal of this research study is to find the highest, safest dose of honokiol (a type of dietary supplement) that can be given to patients who have resectable early-stage NSCLC. Researchers also want to learn if giving honokiol before surger ... Read more >

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chem ... Read more >

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Status: Enrolling

Investigator: Chinemerem Abanonu

Study Coordinator: Frances Saubon

Phone: 713.624.0724

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvemen ... Read more >

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC)

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Soli ... Read more >

Vaccination Responses in Lung Transplant Recipients

Status: Enrolling

Investigator: Howard Huang

Study Coordinator: Lindsay Barter

Phone: 502.417.6664

The purpose of this project is to build a consortium of lung transplant centers wherein blood samples will be collected to evaluate the humoral and immune response of lung transplant recipients to vaccinations, such as COVID-19 and influenza. Th ... Read more >